Modality
mAb
MOA
IL-23i
Target
VEGF
Pathway
RNA Splicing
Cervical Ca
Development Pipeline
Preclinical
~Oct 2016
→ ~Jan 2018
Phase 1
~Apr 2018
→ ~Jul 2019
Phase 2
Oct 2019
→ Feb 2028
Phase 2Current
NCT08493549
1,833 pts·Cervical Ca
2019-10→2028-02·Completed
NCT07779813
1,377 pts·Cervical Ca
2022-06→2026-02·Recruiting
3,210 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-02-052mo agoPh2 Data· Cervical Ca
2028-02-151.9y awayPh2 Data· Cervical Ca
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P2
Complet…
P2
Recruit…
Catalysts
Ph2 Data
2026-02-05 · 2mo ago
Cervical Ca
Ph2 Data
2028-02-15 · 1.9y away
Cervical Ca
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08493549 | Phase 2 | Cervical Ca | Completed | 1833 | ACR20 |
| NCT07779813 | Phase 2 | Cervical Ca | Recruiting | 1377 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| GSK-6983 | GSK | Phase 2 | ALK | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| Zenotapinarof | Vertex Pharma | Preclinical | CD38 | |
| Pemicapivasertib | Legend Biotech | Phase 3 | VEGF | |
| Sematapinarof | Legend Biotech | NDA/BLA | VEGF | |
| LEG-6533 | Legend Biotech | NDA/BLA | VEGF |